SM
LENZ

Scoggin Management’s LENZ Therapeutics LENZ Stock Holding History

Scoggin Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$994K Buy
175,000
+50,000
+40% +$403K 0.11% 47
2026
Q1 		$1.14M Hold
125,000
– – 0.11% 39
2025
Q4 		$2M Sell
125,000
-100,000
-44% -$2.91M 0.31% 37
2025
Q3 		$10.5M Buy
225,000
+25,000
+13% +$919K 1.64% 14
2025
Q2 		$5.86M Buy
200,000
+100,000
+100% +$2.72M 1.22% 23
2025
Q1 		$2.57M Buy
+100,000
New +$2.46M 0.72% 35

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Scoggin Management's LENZ Position: Q2 2026 in Review

Scoggin Management increased its LENZ Therapeutics (LENZ) stake by 40% in Q2 2026, buying an estimated $403K and bringing the position to 175,000 shares worth $994K. The position accounts for 0.11% of the portfolio, ranked #47.

Scoggin Management first reported a position in LENZ in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.5M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Scoggin Management held 175,000 shares of LENZ Therapeutics worth $994K as of Q2 2026.
  • Scoggin Management bought 50,000 LENZ Therapeutics shares in Q2 2026, an estimated $403K.
  • LENZ Therapeutics made up 0.11% of Scoggin Management's portfolio in Q2 2026, its #47 holding.
  • Scoggin Management first reported a position in LENZ Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Scoggin Management's LENZ Therapeutics position peaked at $10.5M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Scoggin Management's 13F filing for Q2 2026, filed 14 Aug 2026.